1.Implementation of ECG Monitoring System Based on Internet of Things.
Chinese Journal of Medical Instrumentation 2015;39(6):418-420
In order to expand the capabilities of hospital's traditional ECG device and enhance medical staff's work efficiency, an ECG monitoring system based on internet of things is introduced. The system can monitor ECG signals in real time and analyze data using ECG sensor, PDA, Web servers, which embeds C language, Android systems, .NET, wireless network and other technologies. After experiments, it can be showed that the system has high reliability and stability and can bring the convenience to medical staffs.
Electrocardiography
;
Internet
;
Monitoring, Physiologic
;
Reproducibility of Results
;
Wireless Technology
2.Research on design and application of medical waste management system
Minya CHEN ; Yi ZHANG ; Liangliang LU
China Medical Equipment 2014;(10):12-13,14
Objective: Medical waste management is not only the problem of hospital, but also is an important public health problem. Apply modern information technology to insure real-time tracking and monitoring medical waste recycling, storage, disposal, improve medical waste management. Methods: Construct medical waste management system with wireless network, bar code and RFID etc. Results:By this system, transportation, storage and disposal that process of medical waste within the hospital are monitoring and supervision effective. Conclusion:The collection and transportation sectors of medical waste have been standard, to ensure the security, enhanced transparency and improved hospital management.
3.Clinicopathological characteristics of gastric cancer with enteroblastic differentiation
Minya LU ; Lisong TENG ; Guoliang ZHU ; Qilin SHI ; Zhaoming WANG ; Hui XIA ; Xiaolan ZHANG ; Weili WANG ; Piwei HU
Chinese Journal of Clinical Oncology 2019;46(2):69-72
Objective: To investigate the clinicopathological features and molecular phenotypes of gastric cancer with enteroblastic dif-ferentiation (GCED). Methods: A retrospective analysis of 337 patients with gastric adenocarcinoma diagnosed by the pathology de-partment of the First Affiliated Hospital of Zhejiang University in March 2013-2017 was conducted. Of them, 8 patients were diag-nosed with gastric carcinoma with intestinal blastocyte differentiation. All the patients were elderly, including 6 men and 2 women. The onset age was 68-83 years (mean 76.6 years). Two cases had serum AFP≥200 μg/L before treatment. According to the histopatho-logical morphology, the immunophenotype was analyzed by immunohistochemistry, the SALL4 gene was detected using reverse tran-scription-polymerase chain reaction (RT-PCR), and the relevant literature was reviewed. Results: Microscopically, all cases had primi-tive enteroid structures, consisting of cubic or columnar cells with clear cytoplasm, and immunohistochemical staining showed positivi-ty for either AFP and GPC3 or SALL4. The expression of SALL4 mRNA was significantly increased by RT-PCR. Follow-up from 1 to 5 years showed that 5 patients had liver and other organ metastases, 2 patients died, and 1 patient survived without a tumor. Conclusions:GCED is a rare invasive gastric adenocarcinoma with a worse prognosis than that of normal intestinal adenocarcinoma. The treatment of general intestinal adenocarcinoma has little effect. There are some characteristic changes in histology. It would be helpful for diag-nosis and differential diagnosis if clinicians are familiar with the tumor spectrum and genetic characteristics. Target therapy for an origi-nal marker, such as SALL4, has a bright future.
4.Recommendation of Diagnosis and Management for the Infections Related to Immune Checkpoint Inhibitors.
Minya LU ; Li ZHANG ; Yue LI ; Hanping WANG ; Xiaoxiao GUO ; Jiaxin ZHOU ; Lian DUAN ; Xiaoyan SI ; Yingchun XU ; Li ZHANG
Chinese Journal of Lung Cancer 2019;22(10):666-670
Immune checkpoint inhibitors (ICIs) have been widely used in management of malignant tumor. Programmed death ligand 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have been introduced to treat non-small cell lung cancer (NSCLC) in recent years. Currently, PD-1/PD-L1 inhibitors are considered to have minor side effects and do not independently increase the risk of infection. However, they may cause immune-related adverse events (irAEs) that can require immunosuppressive therapy with corticosteroids and/or immunosuppressants, leading to opportunistic infections. Furthermore, there were reports about reactivation of chronic/latent infections without irAEs. Thus, immune checkpoint inhibitor related infections have drawn more and more attention in the world. In this paper, we described the potential mechanism, available clinical data and recommendation of diagnosis and management for PD-1/PD-L1 inhibitor related infections.